Screener
G&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| License and collaboration revenue | $31,738 | $7,470 |
| Operating expenses: | ||
| Research and development | 104,524 | 98,816 |
| General and administrative | 34,429 | 27,940 |
| Total operating expenses | 138,953 | 126,756 |
| Loss from operations | (107,215) | (119,286) |
| Other income (expense): | ||
| Change in fair value of derivative liabilities | 2,500 | 3,200 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's G&A?
- Beam Therapeutics (BEAM) reported G&A of $34.43M in Q1 2026.
- How has Beam Therapeutics's G&A changed year-over-year?
- Beam Therapeutics's G&A increased by 23.2% year-over-year, from $27.94M to $34.43M.
- What is the long-term trend for Beam Therapeutics's G&A?
- Over 4 years (2021 to 2025), Beam Therapeutics's G&A has grown at a 18.8% compound annual growth rate (CAGR), from $57.22M to $113.82M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Beam Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude